News

DA Davidson Revises Price Target for Criteo Stock to $53

DA Davidson Revises Price Target for Criteo Stock to $53

DA Davidson Lowers Criteo Price Target While Maintaining Buy Rating

Recently, DA Davidson made adjustments to its forecast for Criteo S.A. (NASDAQ:CRTO), a leading global technology company specializing in marketing and monetization services online. The firm has reduced its price target from $58.00 to $53.00, but notably, it has kept a Buy rating for the stock, indicating their belief in its investment appeal.

Reasons Behind the Price Target Adjustment

The decision to lower the price target stems from recalibrated estimates from DA Davidson, which indicated a 3% reduction in the 2025 CexT estimate. This decline is largely associated with lowered revenues from Iponweb, a factor that has affected the revised expectations. Furthermore, the analyst has decreased their adjusted EBITDA projection for 2025 by $9 million, bringing the new estimate to $387 million.

Nonetheless, despite these adjustments, DA Davidson continues to express optimism regarding Criteo's stock. Currently trading at approximately $34.40, they consider CRTO shares to be undervalued based on current market conditions and growth potential.

Valuation Metrics and Future Growth Expectation

Criteo’s stock valuation at this point reflects a ratio of 4.7 times the analyst's estimated 2025 EV/EBITDA, a figure described as relatively inexpensive, particularly for a company anticipated to achieve high-single digit growth in the upcoming year. This valuation strongly suggests that investors may find a solid opportunity in Criteo.

Investment Highlights and Risk Profile

Further emphasizing the investment potential, DA Davidson points to Criteo’s projected adjusted EBITDA margins, which are expected to hover around 32% or more. Other positive indicators for investors include the improved risk profile of the company, which has evolved positively in the backdrop of changing privacy features within the Chrome browser. These developments are expected to enhance Criteo's market position further.

Analyst Confidence and Market Outlook

In summary, while DA Davidson has adjusted its price target for Criteo downwards, their sustained Buy rating signals strong confidence in the company’s growth trajectory and financial robustness. The new target of $53 signifies a valuation at 7.5 times the firm’s updated EV/EBITDA estimate for 2025. This outlook not only reassures existing investors but is likely to attract new ones, given the potential on offer in Criteo's business model.

Frequently Asked Questions

Why did DA Davidson lower the price target for Criteo?

DA Davidson adjusted the price target due to a 3% decrease in 2025 CexT estimates and lowered Iponweb revenue projections.

What is the new price target for Criteo?

The new price target set by DA Davidson for Criteo is $53, down from $58.

Does DA Davidson maintain a Buy rating for Criteo?

Yes, despite the price target reduction, DA Davidson maintains a Buy rating, indicating their confidence in Criteo's potential for growth.

What makes Criteo attractive as an investment?

Criteo's attractiveness lies in its projected adjusted EBITDA margins of approximately 32% and its favorable valuation metrics suggesting significant growth opportunities.

How has Criteo's risk profile improved?

Criteo's risk profile has improved due to favorable changes in the Chrome browser's privacy policies, which are expected to enhance its market position.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 2

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 2

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 2

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading

Top 5 Most Recently Viewed Articles

Dylan Media Challenges CLIQ Digital's Proposed Share Buyback

Updated Category News Views 176

CLIQ Digital AG Faces Critical Vote from Major Shareholder CLIQ Digital AG, a well-known entity in the digital services industry, recently found itself at a pivotal moment. Dylan Media B.V., the largest shareholder in CLIQ Digital, has made headlines by declaring its intent to vote against a significant item on the agenda at the upcoming Annual General Meeting. This...

Continue Reading
CW Bancorp Announces Quarterly Dividend for Shareholders

Updated Category News Views 213

CW Bancorp Declares a Refreshing Quarterly Dividend CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, recently announced the approval of a quarterly cash dividend by its Board of Directors. This step signifies the company's ongoing dedication to maximizing shareholder value. The Board declared a cash dividend of $0.23 per common share, illustrating the...

Continue Reading
Celebrating 5 Years: Legacy Leaders at HBCU ELI Shine Bright

Updated Category News Views 209

HBCU Executive Leadership Institute: Five Years of Excellence The HBCU Executive Leadership Institute at Clark Atlanta University has reached a significant milestone, celebrating its fifth anniversary. This program is dedicated to nurturing and developing the next generation of presidents and executives at Historically Black Colleges and Universities (HBCUs). It is an...

Continue Reading
Kuehn Law Investigates StubHub Holdings for Shareholder Rights

Updated Category News Views 103

Kuehn Law Investigates StubHub Holdings for Shareholder Rights NEW YORK – Kuehn Law, PLLC, a law firm dedicated to shareholder litigation, is focused on examining whether certain officers and directors at StubHub Holdings, Inc. (NYSE: STUB) have acted against the interests of shareholders. The firm’s investigation is driven by allegations in a federal securities...

Continue Reading
A Comprehensive Guide to Hard Money Lenders in Real Estate Financing

Updated Category Real Estate Views 690

In real estate financing, money lenders occupy a distinctive niche. They offer alternative funding solutions that diverge from traditional banking institutions. A hard money lender presents a viable option for those seeking quick access to capital or needing help securing loans through conventional means. Comprehending the nuances of this financing avenue is paramount...

Continue Reading